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Low Temperature Plasma (LTP) generates reactive oxygen and nitrogen spe-
cies, causing cell death, similarly to radiation. Radiation resistance results in
tumour recurrence, however mechanisms of LTP resistance are unknown.
LTP was applied to patient-derived prostate epithelial cells and gene expres-
sion assessed. A typical global oxidative response (AP-1 and Nrf2 signalling)
was induced, whereas Notch signalling was activated exclusively in progenitor
cells. Notch inhibition induced expression of prostatic acid phosphatase
(PAP), a marker of prostate epithelial cell differentiation, whilst reducing
colony forming ability and preventing tumour formation. Therefore, if LTP is
to be progressed as a novel treatment for prostate cancer, combination treat-
ments should be considered in the context of cellular heterogeneity and exis-
tence of cell type-specific resistance mechanisms.
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There is much interest in the potential for Low Temper-
ature Plasma (LTP) to be a novel focal therapy for can-
cer [1]. Therefore, this study set out to determine the
mechanism of action of LTP in a near patient model of
prostate cancer. LTP is formed by application of high
voltage across a gas-flow, causing removal and subse-
quent acceleration of gas molecule electrons into sur-
rounding atoms and molecules. A reactive cascade of
interconverting neutral and charged species is created in
the plasma effluent, alongside the emission of UV radia-
tion. Mixing of LTP with gas molecules in the air pro-
duces high concentrations of reactive oxygen and
nitrogen species (ROS and RNS) [2,3] that can cause
oxidative stress, DNA damage [1,2] protein oxidation
[5] and lipid peroxidation in cells [5]. LTP-based treat-
ment of cancer cells is being considered for a variety of
malignancies [6], including prostate cancer [1]. However,
before this mode of treatment can be developed for
clinical use, the full mechanism of action, and potential
mechanisms of resistance, needs to be elucidated.
Oxidative stress, as induced by LTP, is defined by
an imbalance of ROS over cellular antioxidants. Cur-
rent prostate cancer treatments such as radiotherapy
and photodynamic therapy generate ROS, which act
as their primary therapeutic agent [7]. Oxidative
response occurs rapidly through the buffering effects
of enzymatic activities and transcriptional programs.
Gene expression following exposure to reactive species
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generated by ionising radiation, is mediated by multi-
ple transcription factors including Nrf2 and AP-1 [5].
Previous studies, which applied LTP treatment to
established cancer cell lines, have shown that LTP
induces apoptotic cell death [2–4]. However, in pri-
mary prostate basal epithelial cultures LTP can also
induce autophagy and necrosis [1]. Critically, a resis-
tant population of viable cells remains after exposure
to LTP; understanding how these cells survive should
allow optimisation of LTP-induced cell death.
Here, we present an analysis of the signalling events
immediately following LTP treatment of primary pros-
tate basal epithelial cells, directly cultured from normal,
benign and cancer tissues from individual patients.
Whilst we observed the predicted activation of AP-1
and Nrf2 oxidative stress response signalling pathways,
we describe for the first time, activation of Notch sig-
nalling by LTP. Significantly, this occurred in the pro-
genitor cell population only, and not the more
differentiated cells within the cultures. Notch is consid-
ered to be a regeneration signal and marker of self-re-
newing stem cell (SC) populations. Activation of this
pathway has implications for potential resistance to
LTP whilst the selective use of a clinically available
Notch inhibitor has the potential to increase the potency
of ROS/RNS species for prostate cancer treatment.
Indeed, Notch inhibition using gamma-secretase inhibi-
tors induced expression of prostatic acid phosphatase
(PAP), indicative of cell differentiation, and a combina-
tion of Notch inhibition with radiation resulted in
reduced colony forming ability compared to Notch inhi-
bition or radiation alone. In addition, Notch inhibition
reduced or prevented tumour formation in vivo. Before
LTP can progress to the clinic, the mechanisms of resis-
tance need to be elucidated alongside proposed combi-
nation treatment strategies to overcome these. Here, we
propose Notch signalling as a major resistance mecha-
nism that could be exploited for therapeutic purposes.
Materials and methods
Culture of primary prostate basal epithelial cells
For matched organ-confined Gleason 7 prostate cancer and
normal cells, tissue was obtained by needle biopsy immedi-
ately following radical prostatectomy (Fig. 1A). Biopsy
sites were informed by previous pathology, MRI imaging
and palpation. Benign Prostatic Hyperplasia (BPH) and
Gleason 9 tissue were obtained through trans-urethral
resection of the prostate. Tissues were transported in
RPMI-1640 (Gibco, Waltham, MA, USA) supplemented
with 5% FCS (Gibco) and 100 UmL1 antibiotic/anti-my-
cotic solution (Gibco) at 4 °C and were processed, as previ-
ously described [8], within 6 h of surgery. All tissue was
obtained with full ethical permission and informed consent
(REC ref 07/H1304/121). Patient identities were anon-
ymised at source. Primary cells were grown on BioCoatTM
Collagen I coated 10 cm dishes (Corning Inc, Corning,
NY, USA) in SC media, based upon keratinocyte serum
free media (Gibco) supplemented with L-glutamine (Gibco),
SC factor, granulocyte macrophage colony stimulating fac-
tor, cholera toxin, bovine pituitary extract, epidermal
grown factor (Gibco) and leukaemia inhibitory factor [9].
Cells were fed every other day and sub-cultured when con-
fluent using 19 Trypsin-EDTA (Gibco). No cultures used
in this study were passaged more than five times, to limit
divergence from the original donated tissue. Primary cells
were cultured in the presence of irradiated (murine) STO
feeder cells and no antibiotic/anti-mycotics were used to
maintain the cultures. STOs were depleted before any LTP
treatments to remove any mouse cell artefacts.
Selection of basal epithelial sub-populations
Primary prostate epithelial cell cultures are heterogeneous
and subpopulations can be separated using rapid collagen
adherence due to differential expression of a2b1integrin
[10]. Basal epithelial cells were plated onto BioCoatTM Col-
lagen I coated 10 cm dishes (Corning) that had been
blocked for 1 h at 37 °C in 0.3% BSA (Sigma, Gillingham,
UK) PBS (Gibco)(heat treated at 80 °C for 10 min and fil-
tered). After 5 min of incubation at 37 °C, the rapidly
adherent a2b1integrin
hi cells [SC and Transit Amplifying
(TA) populations] were washed in PBS and harvested by
trypsinisation. The non-adherent a2b1integrin
lo cells [Com-
mitted Basal (CB) population] were collected from the
plates after the 5-min incubation and in the PBS washes.
Cells were then treated, depending on the assay to be per-
formed. Staining for a2b1integrin expression uses CD49b
antibody, which detects the integrin a2 protein.
Choice of tissues, LTP dose and post-treatment
time-points in gene expression analysis
Primary culture LTP dose (3 min) and post-treatment
time-points (0.5 and 2 h) for use in analysis of gene
Fig. 1. LTP activates oxidative stress responsive gene expression in primary prostate epithelial cell cultures. (A) Retrieval of targeted needle
biopsies from prostate tumour and from adjacent non-cancerous (normal) tissue. Average gene expression of 12 patient cultures of confirmed
tissue pathology; (B) Normal (n = 3), (C) BPH (n = 3), (D) Gleason 7 (n = 3), (E) Gleason 9 (n = 3) at 2 h post 3 min LTP treatment. Each gene is
represented by a single dot; black – unchanged, red – upregulated ≥ 2-fold and green – downregulated ≥ 2-fold. The solid black diagonal line
represents no change between untreated to treated expression, the flanking dashed lines – a ≥ 2-fold expression change.
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expression were optimised from previously obtained cell
viability data [1] and preliminary testing on the RT2 Pro-
filer Oxidative Stress qRT-PCR Arrays. (Qiagen, Hilden,
Germany) (Fig. S1). For each tissue pathology; Normal,
BPH, Gleason 7 (G7) Cancer and Gleason 9 (G9) Cancer,
three separate patient samples were used for the qRT-
PCR arrays. Details of all patient cultures used in the
study are provided in Table S1. The G7 samples were
selected as they were biopsied from patients where normal
prostate tissue had also been removed, to give a ‘patient
matched-pair’.
Dielectric barrier discharge jet configuration and
cell treatments
The LTP jet consisted of a quartz glass tube of inner/outer
diameter 4/6 mm, with two copper tape electrodes 20 mm
apart. One electrode was powered (6 kV sinusoidal voltage
at 30 kHz) and the other grounded. Helium, the carrier
gas, flowed at two standard litres per minute and was fed
with 0.3% molecular oxygen admixture. Cells were exposed
to the LTP jet at a distance of 15 mm from the end of the
bottom electrode for 180 s in 1.5 mL centrifuge tubes, sus-
pended in 1.5 mL of respective media or treated directly in
6-well or 12-well plates (Sarstedt, Numbrecht, Germany).
The distance between the end of the glass tube and the
media surface was ~ 2 mm. Treatment times up to 600 s
did not raise the surface temperature of culture media
above 36.5 °C, measured using a thermocouple. The tem-
perature and relative humidity of the laboratory were
~ 20 °C and ~ 25% respectively.
RT2 profiler PCR oxidative stress arrays
Oxidative stress arrays were purchased from Qiagen. RNA
was reverse transcribed to cDNA with the RT2 First
Strand Synthesis kit (Qiagen). The cDNA was combined
with SYBR Safe Mastermix (Qiagen) and aliquoted across
the array plate. All array plate qRT-PCR was performed
using the C1000 Thermal Cycler and CFX96 Real-Time
System (BioRad, Hercules, CA. USA) under the RT2
Array qRT-PCR protocol; –10 min, 39 cycles of 95 °C for
10 s, 60 °C for 1 min. Data was assimilated using the
CFX Manager 2.0 (BioRad) and analysed using the Qia-
gen online Data Analysis Center (http://www.qiagen.com/
gb/shop/genes-and-pathways/data-analysis-center-overview-
page/). Gene expression scatterplots generated in the soft-
ware were of the Log10 2
DDCt values plotted against each
other (treated/untreated), significant upregulation was
defined as a ≥ 2-fold change in expression. The Qiagen
Oxidative stress response arrays were qRT-PCR plates
consisting of 84 wells containing gene-specific primers to
transcripts responsive to oxidative stress, five wells for
house-keeping genes (HPRT1, GAPDH, B2M, RPLP0, B-
ACT) for relative fold change quantification, PCR control
wells in triplicate, reverse transcription control wells in
triplicate and a single genomic DNA contamination con-
trol well. Notch signalling arrays were processed in the
same way.
SDS/PAGE and Western blotting
Cell lysates were either prepared from frozen pellets or
cells were lysed in 6-well plates following LTP treatment.
Cell pellet lysates were prepared using CytoBusterTM Pro-
tein Extraction Reagent (Novagen, Burlington, MA, USA)
with protease inhibitors (Roche, Burgess Hill, West Sussex,
UK), cell debris removed by centrifugation (17 000 g,
5 min) and protein content measured by PierceTM Bicin-
choninic acid Protein Assay Kit (Thermo Fisher Scientific,
Waltham, MA, USA). 20 lg of protein was loaded per
well with the appropriate amount of 49 SDS protein sam-
ple buffer (40% glycerol, 240 mM Tris-HCl pH 6.8, 8%
SDS, 0.04% bromophenol blue, 15% beta-mercap-
toethanol). In-plate cell lysates were prepared using 49
SDS protein sample buffer. Samples were sonicated for
3 9 10 s using the Sanyo Soniprep 150 (MSE, London,
UK) and incubated at 95 °C for 5 min. Forty microlitre of
lysate was loaded per well. Protein samples were resolved
on 10% acrylamide gels. Precision Plus Kaleidoscope Pre-
stained Protein Standards (BioRad) was used as marker
for all gels. Proteins were transferred onto PVDF Immo-
bilon P membranes (Merck Millipore, Burlington, MA,
USA) for 1 h at 100 V. Primary and secondary antibodies
and dilutions used in Table S2. Membranes developed in
BM Chemi-luminescence western blotting Substrate (POD;
Roche) and viewed on the GeneGnome XRQ (Syngene,
Cambridge, UK).
Densitometry analysis
All western blot images were edited on GIMP 2.8 (GNU
Image Manipulation Program, Berkeley, CA, USA) prior
to densitometry analysis. Densitometry acquisition was per-
formed using Image Studio Lite 5.2 (Licor, Lincoln, NE,
USA). Readout from the densitometry acquisition allowed
results to be analysed using Excel 2010 (Microsoft, Red-
mond, WA, USA). All graphs and statistics were prepared
and performed on PRISM 7 (GraphPad, San Diego, CA,
USA).
Statistical analyses
All statistics performed on patient grouped gene expression
were unpaired t-tests (one-tailed). Degrees of freedom were
dependent on the n of the experiment which is supplied in
the figure legends. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001,
and ****P ≤ 0.0001. The microarray data analysed by the
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Transcriptome Analysis Console program using ANOVA,
values are provided in Table S3.
RNA integrity and affymetrix clariom D
microarray
RNA integrity testing was performed on all samples prior
to microarray analysis, using the 2100 Bioanalyzer (Agilent,
Santa Clara, CA, USA) and all samples returned a maxi-
mum RIN score of 10. Microarray analysis was performed
by Eurofins using the Clariom D Microarray system (Affy-
metrix, Santa Clara, CA, USA).
Bioinformatic analysis of microarray data
Initial analysis was performed using Gene Level Differential
Expression Analysis on the Transcriptome Analysis Console
Ver.3.1.0.5 (Affymetrix) equipped with the Clariom_
D_Human.na36.hg.probeset. Pre-processed data were anal-
ysed using the LIMMA (Linear Models for Microarray and
RNA-Seq Data) within the R numerical environment (Team
RC. R: A language and environment for statistical comput-
ing. Foundation for Statistical Computing, Vienna, Austria
(https:///www.R_project.org/). Cell of origin and treatment
type were modelled in the design matrix. Significant results
after empirical Bayesian smoothing of the standard errors
were extracted using a false discovery rate threshold of 0.025.
No log-fold change threshold was applied. After LIMMA
analysis, results were analysed using gene set enrichment. The
topGO package was used (Rahnenfuhrer AAaj. topGO:
Enrichment Analysis for Gene Ontology. R package version
2.28.0 ed 2016). GO testing was performed using the
‘weight01’ algorithm with Fisher’s statistics. A threshold of
0.05 was used to select significant results. As well as GO
enrichment, pathway analysis was performed against the
KEGG [11] pathways. Significant results from the LIMMA
analysis were analysed with a P-value threshold of 0.05.
Quantitative reverse transcription PCR (qRT-PCR)
– Cell line and array validation
All RNA extractions (both for individual qRT-PCRs and for
the RT2 Profiler qRT-PCR Arrays) were performed on cell pel-
lets previously stored at 80 °C or by direct in-plate lysis (ad-
dition of complete RLT buffer followed by storage at 80 °C
overnight) using the RNeasy Micro Kit (Qiagen) following the
manufacturer’s instructions for the animal cell protocol. Geno-
mic DNA contamination was removed by on-column applica-
tion of the RNase-free DNase Set (Qiagen). cDNA was
synthesised using Superscript III cDNA synthesis kit (Invitro-
gen, Carlsbad, CA, USA), with reactions placed in GeneAmp
PCR System 9700 thermal cycler (Applied Biosystems, Foster
City, CA, USA). Taqman qRT-PCR was then performed in
FrameStar 96 qRT-PCR plates (4titude, Dorking, UK). Input
cDNA was standardised at 30 ng per well. The mastermix used
was TaqMan Fast Universal Master Mix (Applied Biosys-
tems). Probes used in experiments are provided in Table S4.
qRT-PCR was performed using the C1000 Thermal Cycler
and CFX96 Real-Time System (BioRad) under the following
protocol; 95 °C – 10 min, 39 cycles; 95 °C for 10 s, 60 °C for
1 min, 4 °C Hold. Data was assimilated using the CFX Man-
ager 2.0 (BioRad) and analysed using the 2DDCt method, nor-
malising to 18S. All boxplots and statistics were prepared and
performed on PRISM 7 (GraphPad).
Immunofluorescence
Cultured primary cells were deposited into BioCoat Collagen
I 8-well chamber slides (Corning) – 10 000 cells per well. An
LTP dose of 1.5 min was administered directly to the well
and cells were fixed 30 min after treatment with 4%
paraformaldehyde. The reduced dose was used due to the
smaller liquid volume of the well to limit cell death following
treatment. Cells were permeabilised (if required) for 10 min
in 0.5% Triton X-100 (Sigma) in PBS. Cells were blocked in
10% goat serum in PBS for 1 h. Primary antibody was
diluted in 10% goat serum in PBS. For antibodies and dilu-
tions used see Table S2. The chamber slides were left over-
night at 4 °C on SSM3 orbital shaker (Stuart, Staffordshire,
UK) at 50 r.p.m. After overnight incubation, a secondary
Alexafluor 568 antibody - anti-rabbit A11036 (Invitrogen),
anti-mouse A11031 (Invitrogen) -diluted 1 : 1000 in 10%
goat serum was then applied for 1 h at room temperature.
The chamber of the slides was then removed and Vectashield
with DAPI (Vector, Peterborough, UK) was applied to the
slide with a coverslip applied on top before being sealed.
Slides were imaged on the DM IL LED Microscope (Leica,
Wetzlar, Germany) with the DFC365 FX Camera (Leica)
under Cy3 and DAPI filters. Images were viewed and stored
using the LAS X program (Leica).
Colony forming assay
Cultured primary prostate epithelial cells were plated and
treated with 10 lM RO4929097 or 0.1% DMSO for 3 days
and then exposed to 2 Gy radiation. Cells were selected and
plated (93) at colony forming density and allowed to grow.
After 7–10 days colonies were stained with crystal violet (1%
crystal violet/10% ethanol/89% PBS) and counted.
In vivo experiments
Patient-derived xenografts were grown in Rag2/gamma
(C)/ mice and were harvested at appropriate size. Cells
were then disaggregated and depleted for mouse cells, counted
and then treated for 24 h with 10 lM RO4929097 or 0.1%
DMSO, ex vivo. Following incubation, cells were injected (103
or 104 cells) with 2 9 105 STO feeder cells and 80 lL matrigel,
subcutaneously. Tumour volume was measured.
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Results
LTP induces an oxidative stress response in
primary prostate basal epithelial cultures
To assess the cellular reaction to LTP, we assembled a
panel of primary prostate epithelial cultures from normal
(n = 3), benign (n = 3) and malignant tissue [Gleason 7
(G7) (n = 3) and Gleason 9 (G9)(n = 3)] and analysed
the expression of 84 genes at 2 h following a 3-min LTP
dose, using Qiagen Oxidative Stress Profiler Arrays
(Fig. 1B–E). The time and dose were chosen after opti-
misation experiments (Fig. S1), as there is a very rapid
and transient upregulation of the anti-oxidative
responses. The normal and G7 cultures originated from
three patients and were defined as ‘patient matched-
pairs’. This afforded a true comparison between normal
and cancer gene transcription (Table S1).
The transcriptional signature after LTP treatment
indicated rapid upregulation of (a) redox enzymes
(HMOX1, SRXN1, TXNRD1), (b) chaperones
involved in protein folding and autophagy (SQSTM1,
HSPA1A) and (c) a MAPK phosphatase (DUSP1)
(validation in Fig. S2). HMOX1 and HSPA1A were
upregulated in all pathology types. The other genes
were upregulated in at least two tissue pathologies,
except for DUOX1 and GPX4, which were exclusively
responsive in a single Gleason 9 sample. Since these
genes were upregulated across all, or several, tissue
pathologies, we next sought to identify common
upstream transcription factors that could govern the
LTP response of the prostate epithelial cells.
Oxidative stress transcription factors are
activated in LTP-treated primary cultures
Previous studies have implicated activation of Nrf2,
the canonical oxidative stress transcription factor, and
AP-1, a regulator that balances cell growth and death,
in LTP response [2,12–14]. Protein analysis of three
patient matched-pairs indicated that, within 30 min of
treatment, LTP stimulates both an accumulation of
Nrf2 and activation of the AP-1 pathway, through
characteristic phosphorylation of both JNK and Jun
(Figs 2 and S5). Protein levels of Keap1 remained con-
stant after treatment, indicating that Nrf2 accumula-
tion is due to cellular redox changes, rather than a
manipulation in the amount of its negative regulator.
Cellular stress pathways are activated by LTP
The oxidative stress PCR arrays clearly present a bias
by nature of design, restricted to identifying only
oxidative stress response post-LTP. Therefore, whole
transcriptome analysis of 6 primary samples (29 patient
matched pairs and 29 Gleason 9) using microarrays
was performed to assess the impact of LTP on global
gene expression (Fig. 3). The patient-matched pairs
didn’t exhibit a divergent gene signature after treatment,
(Fig. S3) so all samples were grouped for further analy-
sis and not segregated by disease status. Overall, 544
transcripts were significantly upregulated and 101 genes
were significantly downregulated (fold change ≥ 2,
P ≤ 0.05, relative to untreated) between the six samples
(Fig. 3A). The microarray confirmed the oxidative
stress gene upregulation, with HSPA1A, HMOX1 and
SQSTM1 all significantly upregulated in LTP treated
samples (Fig. 3B). From initial observation (Fig. 3B
and Table S3) and after LIMMA (Linear Models for
Microarray and RNA-Seq Data) analysis (Fig. 3C and
Table S5), which accounts for a gene’s inherent biologi-
cal expressional variability, several signalling pathways
were activated by LTP.
A striking activation of Notch target genes (e.g.
NRARP, HES1, HEY1 etc.) was detected. Indeed, the
top hit from the entire microarray was NRARP, a tar-
get and downstream effector of Notch, and a negative
regulator of cleaved Notch (Fig. 3B,C). Expression of
9 genes was assessed by qRT-PCR in four primary cul-
tures to validate the microarray data-set (Fig. S4).
These genes were chosen to represent Notch (NRARP,
SOX9, HES1), AP-1 (JUN, FOSB, DUSP10) and
Nrf2 (HMOX1, SQSTM1) stress responses. Whilst
some of these genes failed to achieve ≥ 2-fold upregu-
lation cut off in all samples in the qRT-PCR, the over-
all validation was successful in confirming the
robustness of the microarray dataset.
AP-1 signalling and Notch1 signalling is activated
by LTP in prostate basal epithelial cells
The upstream components of the signalling pathways
identified as responding to LTP in the microarray were
assessed by Western Blot, through observation of pro-
tein changes over a 2-h time-course in two matched
pairs. We monitored AP-1 transcription factor further
by assessing levels of Jun and P-Jun, one of the sub-
units of the AP-1 transcription factor (Fig. S6). We
monitored activation of Notch by assessing levels of
Notch and levels of NICD (Notch intracellular
domain), which is cleaved, active Notch (Fig. 4). Total
levels of Notch1 were unchanged by treatment. How-
ever, NICD, the active cleaved form of Notch, accu-
mulated in treated cells to ~ 5-fold greater levels than
in untreated cultures half an hour after LTP dose,
though there was wide variation between the samples.
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Endogenous Notch gene expression and
activation of Notch signalling in response to LTP
are both enhanced in the progenitor cell
population
Active Notch signalling is associated with epithelial SC
pools and is a determining factor in cellular identity
[15]. NOTCH1 and HES1 are expressed at high levels
in the SCs of primary prostate basal epithelial cultures,
in comparison to more differentiated CB cells, and the
receptor has also been implicated as a key determinant
of the human basal SC population [16,17] (Fig. 5).
Preliminary protein analysis of Notch1 signalling in
the selected basal epithelial cell populations (SC/TA
and CB) revealed activation after LTP treatment
(Fig. 6A,B) with the predominant activation being
seen in the SC/TA population. Immunofluorescence
indicated an increase in Notch post-LTP treatment,
but nuclear staining of the active NICD was only
observed in treated SC/TA cells (Figs 6C and S7).
Preferential activation of Notch in the progenitor cells
Fig. 2. LTP causes accumulation of Nrf2
and activation of AP-1. (A) Western blot
analysis of stress activated transcription
factors in untreated (U) and treated (T)
cells, 0.5 and 2 h after treatment. Three
matched pairs were tested with one
example represented here and two further
examples in Fig. S5. (B) Boxplot
densitometry analysis of the protein data.
All six patient samples (normal n = 3,
cancer n = 3) are plotted as single points
and mean fold change represented by ().
The red dotted line represents a 2-fold
change.
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Fig. 3. Whole transcriptome analysis reveals activation of multiple signalling pathways by LTP. Microarray analysis of gene expression 2 h
after 3 min LTP dose in primary prostate cultures. Patient samples were grown in culture from normal prostate (two samples), Gleason 7
(two samples) and Gleason 9 cancer (two samples). Gene expression was assessed 2 h after 3-min LTP dose. (A) Volcano plot of
significantly changed gene expression (P =≤ 0.05, fold change cut-off is ≥ 2-fold) in Treated versus Untreated samples. 645 transcripts were
altered by LTP – 544 upregulated, 101 – downregulated. (B) Heat map of genes of interest across the six samples tested. (C) Expression
plot showing genes that passed LIMMA.
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was further confirmed by upregulation of NRARP fol-
lowing LTP, where all three cultures exhibited signifi-
cantly higher responsive expression of the negative
regulator in their SC/TA population over that
observed in CB cells (Fig. 6D). Jun was phosphory-
lated in all primary cultures exposed to LTP (peak
intensity at 1 h) following treatment but was not cell-
specific (Fig. S9).
Fig. 4. LTP activates Notch signalling in primary prostate epithelial cell cultures. (A) Western blot time-course of protein alterations in Notch
signalling pathways following 3 min plasma treatment in two matched pairs of normal and cancer biopsies (one shown here and one in
Fig. S7). (B) Densitometry analysis of Notch1 activation by LTP in all four samples.
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Inhibition of Notch using gamma-secretase
inhibitors induces cell differentiation and reduces
colony forming efficiency
Notch inhibition can be achieved by addition of
gamma-secretase inhibitors, which prevent cleavage of
Notch to its active form. After addition of RO inhibi-
tors RO (RO4929097), DAPT and Dibenzazepine
(DBZ), assessment of gene expression was carried out
using a Qiagen Notch Signalling PCR Array. The data
confirmed inhibition of Notch1, and a coincident
decrease in HES1 and HEY1, which are downstream
Notch signalling transcription factors (Fig. 7A). There
was however a compensatory increase in Notch4 gene
expression and upregulation of DLL1, which is a
Fig. 5. Protein and RNA expression of Notch in primary prostate epithelial cell cultures. (A) and (B) – Expression of Notch receptors and
target genes in primary prostate epithelial SC and CB cells. Silenced gene PDYN and Active gene RPLP0 are provided as negative and
positive expression controls respectively. (Data obtained from Birnie et al. [16]), (Significance; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001,
****P ≤ 0.0001). (C) Expression of Notch receptors and target proteins in primary prostate epithelial cells (one patient culture shown).
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Fig. 6. Notch signalling is more active in the SC/TA population, than in CB cells, after LTP treatment. (A), (B) Western blot and densitometry
analysis of Notch1 activation in prostate epithelial sub-populations 30 min after 3 min LTP dose (one sample shown, two more samples
shown in Fig. S8). (C) Immunofluorescence images of Notch1 in prostate epithelial sub-population cells 30 min after 3 min LTP dose.
Validation of cellular fractionation is shown by the CD49b staining of SC/TA. Nuclear foci in SC/TA population highlighted in expanded box
(white arrows). (D) Gene expression boxplots of sub-population NRARP expression 2 h after 3 min LTP dose. Each biological repeat (n = 3)
is plotted as a point and the mean expression value is represented as a (). The red line shows a 2-fold change in expression. Unpaired
t-tests (one-tailed) were performed between each subpopulation. White scale bars = 25 lM. (*P < 0.05, **P < 0.01).
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ligand that binds to the extracellular domain of the
Notch receptor. As a result of Notch inhibition, we
observed an induction of cellular differentiation in the
primary prostate epithelial cell cultures, as shown by
an increase in PAP expression (Fig. 7B). Functionally,
this inhibition of Notch resulted in a decrease in col-
ony forming efficiency of 30–60% in SC. The effects
of Notch inhibition in TA/CB cells gave a wide varia-
tion in response in different patients. In both SCs and
TA/CB cells, the application of 2 Gy radiation, in
combination with Notch inhibition resulted in strik-
ingly reduced colony forming ability (> 70% reduction
in SCs and > 60% reduction in TA/CB cells (Fig. 7C).
Inhibition of Notch in a patient-derived xenograft
reduces both tumour-initiating ability and
tumour growth
In order to assess the effect of Notch inhibition on
tumour growth in vivo, disaggregated cells from a
patient-derived xenograft were treated in vitro, then re-
injected back in vivo. Effects on tumour initiation and
growth post-treatment were both monitored (Fig. 8A).
Depending on the number of cells used in the injec-
tion, tumour growth was either prevented, delayed or
reduced. In addition, once the tumours had been col-
lected and disaggregated with mouse cells removed,
the remaining human cells were stained for an indica-
tor of cell differentiation, PAP, and it was found that
all tumours which grew post-Notch inhibition had
increased expression of PAP (Fig. 8B).
Discussion
This is the first report of global gene expression analy-
sis of LTP in multiple patient-derived primary epithe-
lial prostate cells, including matched pairs of normal
and cancerous prostate from the same patient. Induc-
tion of oxidative stress, with typical accumulation of
the antioxidant master regulator, Nrf2 and activation
of AP-1 transcription factor was the primary and pre-
dictable observation, but nonetheless novel because of
the cell model that we used. LTP-induced oxidative
stress has previously been observed in cancer cell lines
[1,18]. Differences in base Nrf2 levels and the kinetics
of Jun phosphorylation, as an indicator for AP-1 sig-
nalling, were likely due to the innate variability in the
oxidative stress buffering capacity of normal and
cancerous epithelia and also the different patient ori-
gins of the tissue, all of which will have variable levels
of antioxidant and ROS scavenging proteins. To our
knowledge, this study represents the only true normal-
cancer comparison of tissue isolated from the same
patient to date, with no artificial immortalisation or
culture media differences to add further variables and
artefacts upon analysis.
The ‘selective effect’ of cancer cells showing more
sensitivity to LTP treatment than their normal coun-
terparts has been a contentious claim in the field of
anti-cancer plasma treatment, and significantly our
study showed no such ‘selective effect’. Studies that
arrive at this conclusion either used normal cells from
different organs (to the tumour cell origin) [19–22] or
compared epithelial with mesenchymal cells [13]. When
normal and cancer from the same tissue and cellular
origin have been compared [20], inter-patient variance
and the imposed immortalisation of the ‘normal’ cell
line have not been considered.
In the global gene expression analysis of LTP-treat-
ment in patient-derived cancer cells, activation of
Notch signalling was identified as a novel pathway.
We have shown for the first time that LTP activates
Notch signalling, with (a) stimulation of downstream
genes, (b) cleavage of the receptor to release the active
NICD and (c) nuclear localisation of the transcription
factor exclusively in the progenitor cell fraction of pri-
mary prostate epithelial cell cultures. Notch signalling
is important in prostate organogenesis [23], develop-
ment, differentiation, and tumourigenesis (reviewed in
[24]). The pathway regulates self-renewal (asymmetric
division) and prevents differentiation in normal and
cancer SC populations [15,25–27]. Notch signalling
also defines the self-renewal capacity of bipotent basal
SCs in the human prostate [17]. Both Notch and
Notch ligand-receptor proteins are expressed in pri-
mary cultures (Fig. 5). Application of gamma-secretase
inhibitors to prevent cleavage of the NICD and activa-
tion of Notch signalling, with and without ionising
radiation, reduced the self-renewal capabilities of pros-
tate CSCs, both in vitro (Fig. 7C) and in vivo (Fig. 8)
Fig. 7. Exposure of primary prostate epithelial cells to a gamma-secretase inhibitor results in Notch inhibition, cell differentiation and a
reduced colony forming ability (A) Primary prostate epithelial cell cultures were treated with 10 lM RO and the gene expression assessed
using Qiagen Notch Signalling PCR Array. Shown are the fold changes of a selection of Notch1 signalling genes. (B) Inhibition of Notch
using two different gamma-secretase inhibitors (DAPT, DBZ) results in increased prostatic acid phosphase (PAP) protein expression. (C)
Colony forming efficiency of CD133+ and CD133 prostate epithelial cell fractions treated with gamma secretase inhibitors alone or with
radiation (2 Gy) (n = 5). White scale bars = 25 lM.
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by forcing differentiation (Figs 7B and 8B). The
observed variations in colony forming efficiency in
TA/CB cells from different patient samples is probably
the result of different ratios of TA:CB cells in individ-
ual patient-derived cultures, and it would be predicted
that the Notch inhibitor would have more effect on
the TA cells than the CB cells. This data suggests that
Notch signalling is critical for prostate SC mainte-
nance, both in vitro and in vivo, as pharmacological
inhibition of pathway activation results in a reduction
of self-renewal capabilities and pushes epithelial cell
differentiation towards a luminal phenotype.
Low Temperature Plasma treatment induced upreg-
ulation of the negative regulator; NRARP, a Notch-
specific target and downstream effector [28] that pro-
motes Notch degradation leading to release of NCID
[29]. This was confirmed by observation that other
canonical Notch targets were also LTP-responsive,
including HES1 and HEY1, which are transcriptional
repressor proteins, acting to maintain cells in an undif-
ferentiated state, by limiting lineage specific transcrip-
tion factor expression [30]. Constitutive expression of
active Notch1 in embryonic SCs [31] identified a tran-
scriptional signature strikingly similar to that of the
LTP treated patient cultures. Convergent significantly
upregulated hits included; NRARP, HEY1, HES1,
BTG2, GADD45B, SOX9, RHOV, EFNA1, HBEGF,
ITPKC, RIPK4, ATF3 and the EGR factors, supply-
ing correlative evidence that Notch signalling is active,
and acting as a master regulator, in LTP-treated pros-
tate progenitor cells.
Notch signalling has also emerged recently as a
modulator of oxidative stress. Exogenous ROS are
able to upregulate cyto-protective Notch1 signalling
B
A
Fig. 8. Use of gamma-secretase inhibitor to treat patient-derived xenograft cells results in reduced or (A) Tumour growth in vivo of cells
derived from patient-derived xenografts after ex vivo treatment (24 h) with and without gamma-secretase treatment. (B) PAP
immunofluorescence in human cells extracted from patient-derived xenograft tumours, with and without gamma-secretase inhibitor
treatment. White scale bars = 25 lM.
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with associated downstream gene expression in mes-
enchymal SCs [32]. The NICD itself can act as a
potent inhibitor of cell death signals in oxidative stress
conditions [33]. Crosstalk between Notch and other
pathways, such as NF-kB [34–36] and Nrf2 [37] has
been observed, to which some of the transcription fac-
tor’s pleiotropic effects may be attributed.
The activation of stress-activated protein kinases, by
excess ROS, can force SC differentiation [38,39], a fate
that can be averted by Notch signalling [40]. In the pri-
mary cultures following LTP treatment, we observed
both phosphorylation of JNK and subsequent activa-
tion of the Notch receptor. This is accompanied by a
decrease in colony forming efficiency, indicative of a
reduction in self-renewal capability [1], and thus deple-
tion (by symmetrical division), of SCs that fail to trigger
Notch in high ROS conditions. We have previously
observed that a pool of prostate epithelial cells survive
LTP [1]. By activating Notch, the resistant subpopula-
tion could prevent depletion of the progenitor cells by
ROS-induced differentiation (Fig. 5B).
Furthermore, as a result of stimulation of Notch sig-
nalling by radiation, another ROS-inducing therapy,
we have shown that Notch inhibition promotes differ-
entiation and reduces colony forming ability. Indeed,
Notch signalling has been identified as a radiation
resistance mechanism in various cancers, and Notch
inhibition has therefore been proposed as a possible
therapeutic to be included with radiotherapy [41].
More specifically, Notch has been identified as part of
a radiation resistance mechanism particularly within
cancer SCs [42,43]. Our study concurs with this idea,
i.e. that the progenitor cells respond differently to the
LTP treatment, and with increased Notch signalling
could be more resistant to ROS-inducing therapies
than more differentiated cells.
Taken together, we propose a model that postulates
a Notch inhibition/ROS-inducing treatment would be
more effective in prostate cancer therapies than either
treatment alone (Fig. 9). The cell heterogeneity of
prostate tumours, as modelled here by patient-derived
primary epithelial prostate cell cultures means that
there is a heterogeneous response to ROS-inducing
stimuli, including an increased stress response, DNA
damage and cell death in more differentiated cells, and
increased Notch signalling, resistance mechanisms and
cell survival in progenitor cells (Fig. 9A). If a combi-
nation therapy is to be used, combining Notch inhibi-
tion with a ROS-inducing therapy, then decreased
Notch signalling should result in cell differentiation,
Fig. 9. Proposed model for mechanism of
action of Notch Inhibitors in Combination
with ROS-inducing Treatments. There is a
heterogeneous cell response to ROS-
inducing treatments (Radiation or LTP). (A)
Some cells will succumb to increased
ROS, DNA damage and cell death. Other
cells, typically early progenitor cells have
Notch signaling as a resistance
mechanism resulting in maintenance of SC
phenotype, resistance to treatment and
cell survival. (B) Our results propose that a
combination of Notch inhibition with ROS-
inducing treatment results in reduced
Notch signaling and progenitor cell
differentiation thus leading to increased
susceptibility, reduced resistance and
increased cell death.
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reduced resistance and increased susceptibility leading
to increased cell death (Fig. 9B).
The importance of Notch signalling in prostate cancer
is not only significant when considering ROS-inducing
therapies like radiation and LTP, as shown here, but is
also of importance when considering androgen-depriva-
tion therapy (ADT). Although ADT can work initially
for most people, castration-resistant cancer is almost
inevitable [44,45]. Therefore, elucidating the mecha-
nisms of resistance to ADT is necessary. Three recent
studies have shown that Notch signalling can contribute
to resistance to enzalutamide (androgen receptor antag-
onist) [46] and that Notch inhibition combined with
ADT can cause a synergistic therapeutic effect [47,48].
In addition, Notch signalling has also been implicated
in docetaxel resistance [49]. Therefore, Notch inhibitors
are a significant candidate to consider in a variety of
combination therapies, particularly in prostate cancer
[50]. However, despite approvals for clinical use before
implementation, the regulation of Notch signalling in all
cell types within a heterogeneous prostate tumour would
need to be elucidated further since Notch is involved in
many complex cellular processes both in cancer and in
normal tissue, and has been implicated as both an onco-
gene and tumour suppressor [51].
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